JANSSEN-CILAG yesterday
announced a locally signed
agreement with Sanofi-Aventis
Australia Pty Ltd (Sanofi) to
combine efforts to co-promote
their respective diabetes therapies
Invokana (canagliflozin) and Apidra
(insulin glulisine) in Australia,
effective immediately.
The agreement brought together
Janssen’s oral diabetes treatment
Invokana, with Sanofi’s experience
in assisting people living with
diabetes to manage their condition,
Janssen Australia and New Zealand
md Chris Hourigan said.
Invokana is a sodium glucose cotransporter
2 (SGLT2) inhibitors and
Apidra is a short-acting insulin.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jul 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.